Tempero Bio, Inc., a clinical-stage biopharmaceutical company developing transformative treatments for substance use disorders, today announced the closing of a $70 million Series B financing. The ...

In 2024, Moyom Biotechnology completed nearly 100 million RMB of Plan B+ financing, led by Boyuan Capital and SAIC Hengxu ...

Unlike platforms that focus solely on token volume, MEXC takes a selective approach, prioritizing high-potential on-chain ...

Can-Fite’s upfront and royalties on sales upon regulatory approval of Piclidenoson for veterinary use, is projected to be $325 million in the ...

A recent study released by researchers from Pohang University of Science and Technology (POSTECH) opens the door for more effective diabetes research and treatment. The new approach leverages ...

Bio-Techne Corporation today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in ...

Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune ...

The European Commission has cleared a plan by Romania to recapitalise state-owned savings bank CEC Bank with 200 million euro ...

Transgenic animals continue to play an essential role in many aspects of zebrafish research, including the development of disease models. The most widely used system for zebrafish transgenesis is the ...

The authors' demonstration that impaired olfactory perception reduces caterpillar performance and increases susceptibility to parasitism is solid. These findings highlight the ecological significance ...

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to ...

This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes management. A search for NovoPen ® publications from 1985 onwards was ...